Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-effect study of melatonin in childhood autism
2008-001689-97Phase 2Active
- Sponsor
- CHU Rennes
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of melatonin in Autism Spectrum Disorder (ASD), sponsored by CHU Rennes. Primary endpoint: Nocturnal urinary melatonin metabolite excretion. Started Oct 2009; status: active.
02
Drugs
melatonin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2008-001689-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001689-97.